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Abstract. Cot, as well as its murine homologue tpl-2, was 
discovered in a COOH–terminal truncated form that unmasks the 
transformation capacity of the protein. The COOH-terminal 
domain of wt Cot contains an amino acid sequence that is a 
recognition signal for degradation via proteasome, besides, this 
domain of wt Cot is also an autoinhibitory domain of the specific 
activity of the wild type form. These data explain the 
transformation capacity of trunc-Cot/tpl-2, that when 
overexpressed is capable of activating several MAP kinases 
pathways as well as AP-1, NFAT, and NF-κB2 transcriptional 
activities. Earlier sobreexpression experiments lead to the proposal 
that Cot/tpl-2 could be involved in proliferative signalling, but the 
use of new technologies such as genetically modifies mice and 
interference RNA end up with the already accepted hypothesis that 
Cot/tpl-2 is involved in immune innate and adaptive processes. 
Cot/tpl-2 is activated in response to the activation of the TLR/IL-1 
receptor superfamily as well as in response to the activation of 
some receptors of the TNF family. Independently of the cell system  
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it is accepted that in resting cells Cot/tpl-2 forms a stable and inactive complex with 
p105 NF-κB among other proteins to protect it from degradation, adequate TLR/IL-
1R stimulation induces the activation of the IKK complex that targets p105 NF-κB 
to be rapidly degraded by the proteasome pathway to p50 NF-κB, a subunit of the 
NF-κB transcription factor. Consequently Cot/tpl-2 is released from the complex 
and susceptible to transduce the activatory signal, leading to the activation of the 
MEK1-Erk1/Erk2 pathway. However, actually it is not completely understood all 
the requests that Cot/tpl-2 needs to be fully active and to this end it is also accepted 
that Cot/tpl2 requires to be phosphorylated. In addition the possibility that the 
requirements vary from cell system to cell system cannot be excluded. 
Physiologically, Cot/tpl-2 is involved in provoking innate immunity to establish 
adaptive immunity. In fact it is the unique MAP3K that activates Erk1/Erk2 when 
the TLRs/IL-1 receptors are activated and mediates the production of pro-
inflammatory cytokines, such as TNFα, IL-1, or IL-6. More recently it has been 
shown that Cot/tpl-2 has the capacity to regulate the balance between Th1 and Th2 
cytokines. All these data indicate that, although mutations in Cot gene result in the 
expression of a protein linked with cell malignancies, physiologically wt Cot/tpl-2 
is involved in innate and adaptive immunity.  
 
Characterization of Cot/tpl-2 protein 
 
 Cot/tpl-2 is a MAP kinase kinase kinase (MAP3K8) capable of activating 
the MEK1-Erk1/Erk2 pathway. The human Cot gene was identified in a 3´ 
rearrangement form that leads to the expression of a truncated/modified 
protein. The normal homologue has an open reading frame encoding 467 
amino acids. The first 397 are identical to the truncated form (trunc-Cot), 
while the 69 amino acids from the COOH-terminal of wt Cot are replaced by 
18 amino acids without sequence homology in the truncated form (1). The 
murine homologue of the human Cot gene is the tpl-2 gene.  The tpl-2 gene 
was also identified in a similar truncated/modified form (2). The COOH-
terminal domains of both wt Cot and wt tpl-2 are almost identical. The only 
difference between the last 77 COOH-terminal amino acids of the human wt 
Cot and the murine wt tpl-2 are the two conservative substitutions of the 
residues M437 for V and K439 for R. However, there is no similarity in the 
amino acids inserted in either trunc-Cot or trunc-tpl-2. These 
truncations/modifications unmask the transforming capacity of this MAP 
kinase kinase kinase, a property of the trunc-Cot/tpl-2 protein (Fig. 1).  
 Nevertheless, it has been shown that overexpression of the proto-
oncogenic form is also capable of conferring a transformed phenotype to 
established cell lines (3-5). 
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 The COOH-terminal domain of wt Cot contains the 
EMLKRQRSLYIDLGALAGYFNL amino acid sequence that is a 
recognition signal for degradation via proteasome. This degron confers 
instability to other unrelated proteins and accounts for the 2.6-fold lower t1/2 
of wt Cot compared (35 min), to trunc-Cot (90 min). On the other hand, the 
deletion of the 44 amino acids of the COOH-terminal of wt Cot increases its 
specific activity in 3.8 fold, measured as MEK1-Erk1/Erk2 activation, 
indicating that the COOH-terminal domain of wt Cot is also an autoinhibitory 
domain of the specific activity of the wild type form (5) (Fig. 1). In fact, the 
COOH-terminal of tpl-2 is capable of inhibiting the kinase activity of trunc-
tpl-2 “in vitro” (2). Moreover, phosphorylation of the residue S400, which is 
contained in the carboxi-terminal of the wt form but not in the 
truncated/modified form, by extracellular stimuli, increases the specific 
activity of the protein (6). In conclusion, all these data indicate that deletion 
of the carboxi-terminal region of the murine and human wt forms increases 
their kinase activity through two independent mechanisms that leads to an 
increase in the t1/2 and an increase in the specific activity of the kinase, both 
potentiate each other in such a manner that equal amounts of trunc- and wt 
Cot mRNA results in a 10-fold increase in the activity of trunc-Cot.  
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Figure 1. Schematic representation of Cot protein kinase.PartA compares the 
structures of the wt Cot (above) and  trunc-Cot (below) proteins. The last 69 amino-
acids of the carboxi-terminal region from the wt protein have been substituted by 18 
unrelated amino-acids. The alternative translation start methionine (M29) is also 
indicated. Part B shows the different domains of the wt Cot protein. The amino-acid 
sequence of the destabilizing region located at the N terminus is shown. The C-
terminus sequence include both a destabilizing region and a kinase activity 
inhibitory domain. The main phosphorylation sites (residues S62, T290, and S400) 
are indicated. 
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 Two alternative translation initiation sites M(1) and M(29) has been 
described for wt Cot/tpl-2 (7). M(29) wt Cot does not contain the first 29 amino 
acids of M(1) wt Cot and exhibits a three -fold higher t1/2 than M(1) wt Cot (7). 
This data suggests that the N-terminal of wt Cot contains another signal that 
triggers the protein to degradation. In fact antibodies against the C-terminal of 
Cot wt recognized two bands in Western blot analysis, being the one with 
higher mass more rapidly degraded (8-10), although the sequence of amino 
acids in the N-terminal of the protein involved in this process remains to be 
established.  
 
Mutations in Cot/or tpl-2 gene are associated with tumorigenesis 
 
 Increased Cot/tpl-2 activity has been observed in different transformed 
cell types. In fact, different modifications in Cot/tpl-2 have been proposed to 
be responsible for cellular transformation (Table1). Cot was identified in a 
truncated/modified form that occurred as a consequence of a rearrangement 
in the 3´ terminal region of human Cot gene during transfection of the 
genomic DNA of a human carcinoma cell line into hamster SHOK cells; this 
rearrangement induced the transformation of the murine cells (1).  
 The insertion of the Moloney Leukaemia Provirus into tpl-2 gene also 
induced a rearrangement in the 3´terminal region of tpl-2 gene. This tpl-2 
gene reorganization plays an essential role in the progression of T 
lymphomas (11, 12). Similarly, the insertion of the Mouse Mammary Tumour 
Virus (MMTV) in the last intron of tpl-2 gene is associated with transformation 
 
Table 1 
 
Type of mutation Cell line/ tissue Reference 
3´ rearrangement of  
Cot/tpl-2 gene 
Hamster SHOK cells. In vitro 
transfection of human genomic 
DNA  
Miyoshi (1991) 
3´ rearrangement of  
Cot/tpl-2 gene 
Murine T cell. Insertion of the 
Moloney Leukemia provirus 
Patriotis  (1993) 
3´ rearrangement of  tpl-2 
gene 
Mammary gland. Insertion of 
Murine Mammary  provirus 
Erny (1996) 
3´ rearrangement of  Cot  
gene 
Primary human adenocarcinoma Clark (2004) 
Genomic locus 
amplification  
Human breast cancer cells Sourvinos (1999) 
Postraductional 
modifications 
Infection of the human T cell 
leukemia virus type-I 
Babu (2006) 
 
Unknown  Human large granular 
lymphocyte proliferative 
disorder 
Christoforidou (2004) 
Unknown Epstein-Barr virus infection  Eliopoulos (2002) 
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of mammary gland cells (13). More recently, in some human adenocarcinoma 
primary tumors a modification in the 3´ region of Cot gene has been 
confirmed (14). The deletion of the 3´ region of the Cot and tpl-2 genes 
provoke not only the expression of a truncated/modified protein, as explained 
above, but also the deletion of the 3´ untranslated region of both genes that 
harbor three copies of the RNA destabilizing sequence AUUUA. This, results 
in the higher expression levels of their corresponding mRNAs (12, 13).  On 
the other hand, the human Cot genomic locus, without modifications in the 
coding sequence of Cot gene, is amplified in some human breast cancers 
(15). Based on these data it has been proposed that Cot could be a prognostic 
factor in breast cancer development (16). Moreover, a correlation between 
high Cot mRNA levels and human large granular lymphocyte proliferative 
disorder has been also proposed (17). Besides the infection of the human T 
cell leukemia virus type-I (HTLV-I) induces high steady state expression 
levels of the M(29) wt Cot, that as previously mentioned, exhibit a high 
stability, resulting in high levels of Cot activity (18). Cot is also commonly 
highly expressed in Epstein Barr virus -associated malignancies, such as 
nasopharyngeal carcinoma and gastric cancer (19). All these data, indicate 
that increased Cot/tpl-2 activity plays a role in cell transformation, besides 
more recently it has been also proposed that Cot could also participate in cell 
invasion processes (20, 21).  
 However in contrast to the established role of Cot/tpl-2 as an oncogene, it 
has been also reported that wt Cot/tpl-2 can function as a tumour suppressor 
gene, since CD8+ T cell lymphomas are developed in old Cot/tpl-2 KO mice 
(22). In these cells the Cot/tpl-2 downregulation decreases the expression of 
the T cell co-receptor CTL4, which negatively regulate de signals transducer 
through the T cell receptor (TCR).   
 
Regulation of Cot/tpl-2 activity by extracellular signals 
 
 Cot and tpl-2 genes were identified in an oncogenic form; thereby for 
many years, it was expected, that the proto-onco Cot/tpl-2 protein could be 
involved in the intracellular proliferative signals pathways. However, the fact 
that the tpl-2 knock-out mice was resistant to LPS/D-Galactosamine-induced 
pathology, due to the low production of TNFα among other cytokines, 
indicated that, physiologically, endogenous Cot/tpl-2 would be involve in 
innate and adaptive immunity rather in proliferative signals (23). 
 Now it is accepted that Cot/tpl-2 is activated in response to the activation 
of the TLR/IL-1 receptor superfamily as well as in response to the activation 
of some receptors of the TNF family (24-26) and that Cot/tpl-2 plays a unique 
role in inflammatory processes. The TLRs, included in the TLR/IL-1R 
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superfamily, contain an extracellular leucine-rich repeat region and are 
sensors of the infection by pathogens since they recognized the different 
pathogen-associated molecular patterns (PAMPS): bacterial lipopeptides 
(TLRs1, 2, and 6) lipopolysaccharide (TLR4), flagellin (TLR5) and nucleic 
acids (TLRs3,7,8, and 9). The IL-1 receptor subfamily, with an Igg like 
extracellular region, includes receptors for IL-1 (IL-1R), IL-18 (IL-18R, and 
IL-33 (T1/ST2 R). However, despite their different extracellular structure, 
both TLRs and IL-1Rs contain in their intracellular region the TIR domain 
and activate similar intracellular pathways including the recruitment to the 
receptor of some adaptors like MyD88, the activation of the kinases IRAK, 
and the ubiquitination of the TRAF proteins, resulting in the activation of the 
IKK complex (reviewed in 27-29). 
  Independently of the cell system, it is accepted that in resting cells, 
Cot/tpl-2 forms a stable and inactive complex with p105 NF-κB among other 
proteins to protect it from degradation. The interaction between p105 NF-κB 
and wt Cot/tpl-2 was first described as a result of a yeast two-hybrid screen 
(30) and was further corroborated, by the fact that p105 NF-κB knock-out 
macrophages, show normal tpl-2 mRNA levels but tpl-2 protein, could be 
only detected when cells are treated with proteasome inhibitors (8,9). Studies 
performed with overexpressed p105 NF-κB and wt Cot/tpl-2, have indicated 
that Cot/tpl-2 protein interacts with p105 NF-κB trough two different 
domains (31). One interaction takes place through the COOH-domain of wt 
Cot/tpl-2, where a proteasome degradation signal is located. This interaction 
explains why the interaction between p105 NF-κB and Cot/tpl-2 protects 
Cot/tpl-2 from degradation. Another interaction between the kinase domain 
of Cot/tpl-2 and p105 NF-κB has been also proposed (31). This interaction 
does not allow the substrates of Cot/tpl-2, like MEK1, to interact with the 
kinase and to be subsequently phosphorylated (32). Besides, cotransfection 
experiments have also demonstrated that ABIN2 (A20-binding inhibitor of 
NF-κB2) also interacts with wt Cot/tpl-2 in addition to p105 NF-κB (33) 
(Fig. 2).  
 This interaction has been also further confirmed in knock-out ABIN2 
macrophages where, as occurred in p105 NF-κB knockout macrophages, 
endogenous wt Cot/tpl-2 protein is neither detected due to its rapid 
degradation. But, in contrast to p105 NF-κB, the interaction of ABIN2 with 
Cot/tpl-2 does not block its kinase activity (34, 35). All these data indicate 
that both p105 NF-κB and ABIN2 are necessary to form a complex with wt 
Cot/tpl-2 to protect the kinase from the proteasome degradation. Besides 
ABIN2 and p105 NF-κB it has been also reported that a member of the 
kinase suppressor family of RAS  (KSR2) interacts with Cot/tpl-2 when both  
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Figure 2. Mechanisms of Cot/tpl-2 activation. The figure shows a schematic 
representation of the mechanisms involved in the activation of Cot/tpl-2 by 
extracellular stimuli (TLRs/IL-1Rs). A) Cot protein status in basal conditions. In 
unstimulated cells Cot/tpl-2 protein is forming a complex with at least two proteins 
(p105 - NF−κB and ABIN-2), this association maintains Cot/tpl-2 inactive and stable. 
B) Upon ligand binding, activated IKKβ phosphorylates p105 tagging it for 
proteosoma degradation. Other signals, not clearly understood yet, allow Cot 
phosphorylation in different residues C) Cot is then released from its interaction with 
p105 and phosphorylated Cot/tpl-2 activates Erk1/2 pathway which is subsequently 
rapidly degraded by the proteasome. 
 
proteins are overexpressed. The co-expression of KSR2 with wt Cot/tpl-2 
significantly and specifically reduces Erk1/Erk2 and NF-κB activation by 
Cot/tpl-2 (36); however the physiological role of this interaction remains to 
be established. Further studies have to be performed to determine if other 
proteins are part of the p105 NF-κB-ABIN2-Cot/tpl-2 complex (37).  
 Adequate TLR/IL-1R stimulation induces the activation of the IKK 
complex; active IKKβ kinase phosphorylates p105 NF-κB in different 
residues (38-40). These phosphorylations target p105 NF-κB to be rapidly 
degraded by the proteasome pathway to p50 NF-κB, a subunit of the NF-κB 
transcription factor (38-41). Consequently Cot/tpl-2 is released from the 
complex and susceptible to transduce the activatory signal (8, 9, 31, 42). 
Once Cot/tpl-2 is dissociated from the complex is rapidly degraded just upon 
activation, by phosphorylation, of MEK1 (8,9). However, actually it is not 
completely understood all the requisites that Cot/tpl-2 needs to be fully active 
and the possibility that the requirements vary from cell system to cell system 
can not be excluded. In one hand, overexpression of TRAF6, an adaptor that 
mediates the activation of the IKK complex, is sufficient to induce Cot/tpl-2 
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activation in MEF cells (43), but not in HeLa cells (10). Overexpression of 
TRAF6 in HeLa cells induces IκBα degradation, indicating that TRAF6 
overexpression induces the activation of the IKK complex. However, the 
overexpression of this adaptor is not sufficient to induce Cot/tpl-2 activation, 
although TRAF6 is required to activate Cot in response to IL-1 stimulation 
(10). Similarly, in macrophages other TRAF protein, TRAF2, participates in 
the intracellular signalling to activate Cot/tpl-2 in response to TNFα but as in 
the case of HeLa it is not sufficient to induce the activation of the kinase (44). 
All together these data provide evidence that at least two intracellular signals 
are required to induce Cot activation (Fig. 2). One of which, is the 
dissociation of Cot from the inactive complex, being this intracellular 
pathway TRAF dependent, but others signal(s) is (are) required to fully 
activate the kinase. In this context it has been reported that upon cellular 
stimulation Cot/tpl-2 becomes phosphorylated in different residues, but the 
exact role of each of these phosphorylations remains to be elucidated (Fig. 1). 
It has been reported by several groups that in response to extracellular stimuli 
like LPS, TNFα or IL-1, Cot/tpl-2 is phosphorylated in the activation loop of 
the kinase, on residue T290 (45-47). This T290 phosphorylation, seems also 
to play a role in the dissociation of Cot/tpl-2 protein from the NF−κB p105 
complex and it is essential for the activation of Erk1/Erk2 by Cot/tpl-2 (45, 
48). Once Cot/tpl-2 is phosphorylated on residue T290, it phosphorylates 
itself in S62, this autophosphorylation enhances the capacity of Cot/tpl-2 to 
activate the Erk1/Erk2 pathway (45). On the other hand, a phosphorylation on 
the S400 of Cot/tpl-2 by LPS stimulation, is also required for a full Cot/tpl-2 
activation (6). AKT is capable of phosphorylating this residue “in vitro” (49), 
but does not plays any role in the phosphorylation of this residue “in vivo” 
and the identity of this kinase is still unknown (6). All these data indicate that 
in general to activate physiologically Cot/tpl-2 two requirements are 
necessary, dissociation of the inactive complex and an adequate 
phosphorylation state of the protein. 
  The specific kinases that phosphorylate both residues T290 and S400 on 
Cot/tpl-2 protein remain to be identified. However, it has been reported, that 
in response to IL-1 and TNFα stimulation Cot/tpl-2 activation requires the 
activity of a tyrosine kinase of the SRC family (10, 44), thereby it can not be 
excluded the possibility that a SRC tyrosine kinase activity, mediates the 
phosphorylation on residues T290 or S400 or both.  By using immobilized 
metal affinity chromatography (IMAC) and a linear trap mass spectrometer 
analysis, other phosphorylation sites on Cot/tpl-2 proteins have been also 
identified, but the role of these phosphorylations on Cot/tpl-2 protein are still 
unknown (50).   
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 More recently, it has been proposed that Cot/tpl-2 also mediates the 
activation of Erk1/Erk2 in response to the activation of the proteinase 
activating factor 1 (PAR-1) (21) and the adiponectin receptor (51). These two 
receptors contain in their structure the classical seven transmembrane 
domains, but not the TIR domain. Thereby, it is unlikely that these receptors 
could activate Cot/tpl-2 through the Myd88 adaptor. All these data open the 
possibility that Cot/tpl-2 take also part in other type of intracellular signaling 
pathways.   
 
Signal pathways activated by Cot/tpl-2 
 
 Both overexpressed wt Cot/tpl-2 and trunc Cot/tpl-2 are capable of 
increasing the activity of several MAP kinases pathways. Overexpression of 
wt or trunc-Cot/tpl-2 induce an increase in the MAP kinases pathways 
Erk1/Erk2, JNK (52), p38γ, and Erk5 (4). Cot/tpl-2, partially as a 
consequence of the up-regulation of the different MAP kinases pathways, 
induces the activation of several transcription factors, such as AP-1, NFAT 
and NF-κB.  
 Overexpression of Cot/tpl-2 induces AP-1 activity in different cell 
systems (53, 54). This activation is probably mediated by the capacity of Cot 
to stimulate c-Jun and c-Fos activities (4, 55). In this context, it has been 
proposed that the ability of Cot/tpl-2 to induce cellular transformation is 
dependent on its ability to activate these two transcription factors (4, 55).  
 Overexpressed Cot/tpl-2 also up-regulates the NFAT transcriptional 
activity (54). In fact, a physical interaction among both overexpressed 
Cot/tpl-2 and NFATc2 has been also demonstrated (56). In one hand, 
Cot/tpl-2 potentiates NFAT-induced transactivation (57), on the other one it 
has been also reported that Cot/tpl-2 induces an NFAT accumulation in the 
nucleus (58, 59). Since the NFAT transcription factors are regulated at two 
different levels, firstly at the level of subcellular localization and secondly 
at the level of the intrinsic DNA binding activity, it remains to be 
established, whether the reported accumulation of NFAT by Cot/tpl-2 in the 
nucleus, could be a consequence of the increased transactivation of NFAT 
triggered by the kinase, resulting in higher nuclear retention, or Cot/tpl-2 
could also have an active role in the modulation of the NFAT in/out 
shuttling of the nucleus.   
 Different groups have also shown that overexpressed Cot/tpl-2 induces 
the activation of the NF-κB, although the mechanism it still unclear. It has 
been claim that Cot/tpl-2 induces an increase in p65 NF-κB transcription 
factor activity by phosphorylating the residues S276 (60), S311(61),  or S536  
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(62), or  both  S468 and 536 (63). Several groups have stated that the NF-κB 
activation by Cot/tpl-2 is through the activation of the IKK complex (64-70), 
due  to the capacity of Cot/tpl-2 to activate NIK (63, 65), a kinase that 
mediates the activation of the IKK complex (71). Besides, it has been also 
proposed that Cot/tpl-2 is required to induce p105 NF-κB degradation (19, 
30) by phosphorylating p105 NF-κB in a different site than the IKK complex 
(32).  
 The cis-elements of these transcription factors modulated by Cot/tpl-2 
overexpression (AP-1, NFAT, and NF-κB) are conserved in many promoter 
regions, thereby, it should be expected that Cot/tpl-2 overexpression, would 
induce the transcription of many different genes (54, 57, 58, 72). However, 
more recent studies performed in cells; where the Cot/tpl-2 protein is knock-
out suggest that in a physiological context Cot/tpl-2 may be more specific 
than when overexpressed. This is in part due to the fact that Cot/tpl-2 share 
substrates with other kinases. Indeed, overexpression of the Cot/tpl-2 dead 
kinase mutant sequesters MEK-1, that physiologically is also phosphorylated 
by other kinases, such as c-RAF.  
 
Involvement of Cot innate and adaptive immunity 
 
 The physiological activation of Cot/tpl-2 has been extensively studied in 
macrophages after LPS stimulation.  Cot/tpl-2 is the unique MAP3K that 
activates Erk1/Erk2 in response to the activation of TLR4 by LPS in 
macrophages (9, 23, 73, 74) (Fig. 2) without modulating the activation of 
p38, JNK, Erk5, and NFκB (23). In TNFα- or LPS-stimulated macrophages, 
in CD-40- stimulated-macrophages or B cells, as well as in IL-1-stimulated 
HeLa cells, Cot/tpl-2 does not modulated JNK and p38 activation (10, 23, 
43). However in tpl-2-/- MEF cells not only Erk1/Erk2, but also JNK, and 
NF-κB activation are defective when stimulated with TNF whereas only 
Erk1/Erk2 activation is impaired when these cells are stimulated with IL-1. 
Thereby, it has been proposed that the signalling role of endogenous Cot/tpl-
2 is stimulus and cell type specific (60). 
 The ablation of Cot/tpl-2 expression in LPS-stimulated macrophages 
partially blocks TNFα (23) and IL-10 secretion (24), and reduces the 
expression of COX-2 (74). Cot/tpl-2 activation is also required to induce 
Erk1/Erk2 activation when bone marrow derived macrophages are activated 
with peptidoglycan, double-stranded RNA or loxoribine, that are ligands for 
TLR2, TLR3, and TLR7 respectively (24, 26). Cot/tpl-2 is also the sole 
MAP3K that activates Erk1/Erk2 pathway in B cells in response to anti-
CD40 and participates in the secretion IgE (43). In carcinoma Hela cells 
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Cot/tpl-2- MEK1-Erk1/Erk2 pathway is required to produce IL-8 and MIP-1β 
in response to IL-1 stimulation (10). On the other hand, and although Cot/tpl-
2 is involved in the intracellular signalling generated by the activation of 
TLR9 by CpG-DNA, it is not clear whether other MAP3K, besides Cot/tpl-2, 
upregulates the Erk1/Erk2 pathway in response to CpG-DNA stimulation  
(26, 75, 76).  
 The role of Cot in inflammation is not only confirmed by experiments 
performed in intact cells due to its capacity to modulate the production of  
cytokines/chemokines  involved in this process, but it also has been assessed 
“in vivo”. In fact Cot/tpl-2 KO mice have a reduction in caerulein-induced 
pancreatic inflammation upon tpl-2 ablation (77) and  it have  been also 
shown that Cot/tpl-2  plays a role in the  onset of Crohn’s  disease (78)(Fig.3) 
Besides, experiments performed with the Cot/tpl-2 KO mice, as well as with 
intact cells were Cot/tpl-2 is down modulated, have shown that this kinase 
modulates the strict balance between Th1 and Th2 cytokines. It has been 
reported that Cot/tpl-2 is an important negative regulator of Th1-type 
adaptive response due to its capacity to downregulate IL-12 production (75) 
(Fig. 3).  
 Antigen presenting cells from Cot/tpl-2 KO mice stimulated with CpG, 
an activator of TLR9, showed an increase in the IL-12 production (75, 76), 
and this  has been confirmed  “in vivo” by  performing  studies with the 
whole animal (75). More recently, it has been also shown, that antigen 
presenting cells from Cot/tpl-2 KO mice stimulated with LPS or CpG, 
showed not only an increase in IL-12 but also in the production of IFNβ, 
being  concomitant  with  a  reduction  in  the levels  of  IL-10, a  typical  Th2 
 
 
 
Figure 3. Cot/tpl-2 modulates Th1/Th2 response and inflammation. In the figure are 
summarized some data from the bibliography using mice null for the Cot/tpl-2 gene. 
The Cot/tpl-2 KO mice shows a decreased production of inflammatory cytokines such 
as TNFα or IL-1β and an increased production of cytokines characteristic of the Th1 
response like IL-12, IFNβ and decreased production of IL-10. 
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cytokine (76). However, further studies have to be carried on to determine the 
exact role of Cot/tpl-2 in polarizing the immune response to type Th1, since 
IL-12-stimulation  of CD4+ T lymphocytes of Cot/tpl-2 KO mice do not to 
produce IFNγ, another key cytokine  in the Th1 response (79). 
 
Cot/tpl-2 a target of anti-inflammatory drugs 
 
 Cot/tpl-2 and RAF isoforms are capable of activating the MEK1-
Erk1/Erk2 pathway, being Erk1/Erk2 a MAP kinase that phosphorylates 
multiple substrates. However RAF-MEK1-Erk1/Erk2 pathway is activated in 
response to proliferative signals, whereas Cot/tpl-2 mediates the intracellular 
signalling of PAMPs and pro inflammatory cytokines, indicating that Cot/tpl-
2 is involved in innate and adaptive immunity and thereby in inflammation. 
Besides, the Cot/tpl-2 physiological role can not be replace by any other 
protein, indicating that this protein is a very good target to develop new and 
improved anti-inflammatory drugs (80, 81). In fact, several groups and 
companies, have focused in the development of small organic compounds to 
specifically block the kinase activity by occupying the active center of 
Cot/tpl-2.  To date, 1,7-napthyridine-3-carbonitriles, quinoline-3-carbonitriles 
and  thieno[2,3-c]pyridines, have been reported as Cot/tpl-2 kinase inhibitors 
(82, 85). It has been shown, that the 7-amino substituted thieno[2,3-
c]pyridines are capable to inhibit activation of Erk1/Erk2 in bone marrow 
derived macrophages in response to LPS stimulation as well as TNFα secretion 
in human whole blood (85).   Among the quinoline-3-carbonitriles, it has 
been proposed that the 8-bromo-4-(3-chloro-4-fluorophenylamino)-6-[(1-
methyl-1H-imidazol-4-yl)met hylamino]quinoline-3-carbonitrile compound 
is capable to inhibit, at an oral dose of 50 mg/kg, the production TNF-α in a 
LPS-induced rat model (83).  
 More recently, it has appeared the possibility to obtain a specific 
ribozyme to degrade the Cot mRNA.  This catalytic RNA is an adenine-
dependent hairpin ribozyme that specific cleaves “in vitro” the mRNA of 
Cot/tpl-2 between bp +225 and +266 bp (86, 87). Further studies are required 
to determine whether this type of compounds or other improved ones will be 
useful to inhibit specifically the expression of Cot/ tpl-2 “in vivo”. 
 
Conclusion 
 
 Cot gene was identified in 1991, and since then we are beginning to 
understand its physiological role in biological processes. Today, there is also 
a very clear link between inflammation and cancer and Cot/tpl-2 is a good 
example of how a protein that is required to control immune responses 
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properly, playing a role in cell transformation when des-regulated. Now, it is 
also clear that this gene has a unique role in the development of the immune 
responses and in inflammation and thus Cot/tpl-2 is emerging as a very 
interesting target to arise new anti-inflammatory drugs.  However, and as it 
has been discussed here, there are still many questions unresolved  before to 
complete the picture of Cot/tpl-2 activation and function.  
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